Superworth

Medpace profit margin MEDP

Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.

Net margin, 12 months
17.7%
Operating margin, 12 months
21.0%
Net margin on a year earlier
−1.1 pts
Peer median
8.9%

Over the twelve months to Jun 30, 2026, Medpace kept 17.7% of its revenue as net profit, with an operating margin of 21.0%.

Five years earlier its net margin was 17.1%.

The median for 10 diagnostics and research stocks of a similar size is 8.9%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202517.8%21.1%n/a
FY202419.2%21.2%n/a
FY202315.0%17.9%n/a
FY202216.8%19.1%n/a
FY202115.9%17.4%n/a
FY202015.7%18.0%n/a
FY201911.7%14.8%n/a
FY201810.4%14.3%64.2%
FY20179.0%14.9%51.4%
FY20163.2%12.5%52.9%
FY2015n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2617.7%−1.1 pts21.0%
Q1 FY2617.2%−2.1 pts21.0%
Q4 FY2517.8%−1.3 pts21.1%
Q3 FY2518.4%+0.7 pts21.5%
Q2 FY2518.7%+2.0 pts21.4%
Q1 FY2519.3%+3.4 pts21.2%
Q4 FY2419.2%+4.2 pts21.2%
Q3 FY2417.7%+2.3 pts19.7%
Q2 FY2416.7%+0.7 pts18.8%
Q1 FY2415.9%−0.5 pts18.1%
Q4 FY2315.0%−1.8 pts17.9%
Q3 FY2315.3%−1.2 pts18.3%

Against its peers

Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.

CompanyProfit margin
MEDPMedpace17.7%
RVTYRevvity8.2%
LHLabcorp7.0%
DGXQuest Diagnostics9.2%
MTDMettler-Toledo International21.9%
BIOBio-Rad Laboratories8.6%
CAICaris Life Sciences10.6%
ILMNIllumina18.4%
IDXXIDEXX Laboratories25.0%
WATWaters3.6%
IQVIQVIA8.1%
Peer median8.9%

Where Medpace ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Medpace

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.